Scintigraphic evaluation of the nephroprotective efficacy of trimetazidine in patients undergoing endovascular myocardial revascularization

The aim of the study was to perform scintigraphic evaluation of the renoprotective efficacy of trimetazidine in patients who underwent endovascular myocardial revascularization (EMR). The study included 40 patients with ischemic heart disease (35 men and 5 women with the mean age of 56.98+1.40 years) who underwent EMR (stenting of the coronary arteries). All patients were randomized into 2 groups: patients (n=12) who took trimetazidine before angiographic procedures (group I) and patients (n=28) who underwent ER without nephroprotection (group II). Dynamic radionuclide renoscintigraphy with 99mTc-DTPA was performed before and 2 to 3 days after the ER with the calculation of the parameters of renal filtration and excretory functions. Patients of group II after ER showed negative dynamics in the renal filtration function parameters. Thus, there was a significant decrease in the mean value of the total glomerular filtration rate (GFR) mainly due to reduction in the filtration activity of the left kidney. Patients of this group demonstrated significant increase in the radiopharmaceutical clearance half-time from the renal pelvis system (RPS) and from the parenchyma of both kidneys and decrease in the cortical delay index of the left kidney. In the group of patients who were treated with trimetazidine (group I), mean values of parameters of filtration activity of the kidneys did not significantly change as compared with the baseline (before ER) data. In comparison with filtration activity, adverse changes in the processes of renal excretion were observed more frequently in group I. However, in patients of group I, average changes in the scintigraphic parameters reflecting the evacuation function of the kidney parenchyma and RPS were insignificant. The study showed that trimetazidine prevents contrast-induced renal dysfunction in patients who underwent coronary procedures.

контраст-индуцированная дисфункция почек, триметазидин, радионуклидная реносцинтиграфия, contrast-induced renal dysfunction, trimetazidine, radionuclide renoscintigraphy

1. Беленков Ю.Н., Сторжаков Г.И., Терещенко С.Н. и др. Модификация факторов риска и предупреждение органных поражений - преимущества ингибиторов АПФ // Сердечная недостаточность. - 2003. - T. 4, № 1. - С. 34-37.

2. Веснина Ж.В., Гракова Е.В., Крылов А.Л. и др. Сцинтиграфическая оценка влияния эндоваскулярной коронароангиопластики на перфузию миокарда и сердечно-легочную гемодинамику у больных ишемической болезнью сердца // Международный журнал интервенционной кардиоангиологии. - 2011. - Т. 25. - С. 36-41.

3. Веснина Ж.В., Гуляев А.М., Лишманов Ю.Б. Радионуклидная реносцинтиграфия в оценке побочного действия рентгеноконтрастных средств на функцию почек // Бюллетень сибирской медицины. - 2012. - № 5. - С. 97-102.

4. Веснина Ж.В., Литовченко Н.В., Гуляев А.М. и др. Влияние рентгеноконтрастных веществ на основе йода и гадолиния на клеточный состав крови и морфологию почек // Сибирский медицинский журнал (Томск). - 2009. - Т. 24, № 4. -С. 45-49.

5. Веснина Ж.В., Рыбальченко Е.В., Гуляев А.М. и др. Радионуклидная реносцинтиграфия в оценке нефропротективного действия ацетилцистеина // Клиническая медицина. - 2009. - № 10. - С. 37-40.

6. Минушкина Л.О., Затейщиков Д.А., Сидоренко Б.А. Блокаторы эндотелиновых рецепторов - еще одно средство лечения легочной гипертонии // Кардиология. - 2003. - T. 43, № 9. - С. 67-71.

7. Пархоменко А.Н., Брыль Ж.Б., Кожухов С.Н. и др. Новые клинические аспекты патогенетической коррекции ишемических и реперфузионных повреждений // Мойбенко А.А., Косенко В.Е. Эндогенные механизмы кардиопротекции как основа патогенетической терапии заболеваний сердца / под ред. А.Н. Пархоменко. - Киев: Наукова думка, 2008. - C. 376-387.

8. Пентюк Н.О. Фармакологічна корекція нефротоксичноi дi індометацину за допомогою триметазидину // Ліки. - 2000. - Т. 6. - С. 21-24.

9. Титова В.В., Давыдов С.И., Бабаева А.Р. Предуктал МВ в комбинированной терапии острого коронарного синдрома: антиангинальная активность и влияние на функцию эндотелия // Consilium Medicum (Кардиология). - 2012. - Т. 14, № 1. - С. 30-33.

10. Bartholomew B.A., Harjai K.J., Dukkipati S. et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification // Am. J. Cardiol. - 2004. -Vol. 93, No. 12. - P. 1515-1519.

11. Bellomo R., Kellum J., Ronco C. Acute renal failure: time for consensus // Intensive Care Med. - 2001. - Vol. 27. - P. 16851688.

12. Branten A.J.W., Vervoort G., Wetzels J.F.M. Serum creatinine is a poor marker of GFR in nephrotic syndrome // Nephrol. Dial. Transplant. - 2005. - Vol. 20. - P. 707-711.

13. Brinker J. What every cardiologist should know about intravascular contrast // Rev. Cardiovasc. Med. - 2003. - Vol. 4 (Suppl. 5). - P. S19-S27.

14. Cau J., Favreau F., Tillement J.P. et al. Trimetazidine reduces early and long-term effects of experimental renal warm ischemia: a dose effect study // J. Vasc. Surg. - 2008. - Vol. 47, No. 4. -P. 852-860.

15. Creagh T., Lanigan D., Dolan J. et al. Pharmacological manipulation of acute cyclosporin ischemic renal injury with trimetazidine // J. Urol. - 1993. - Vol. 149. - P. 915-917.

16. De Santo N.G., Cirillo M., Perna A. et al. The kidney in heart failure // Semin Nephrol. - 2005. - Vol. 25, No. 6. - P. 404-407.

17. Eriksen R., Vegsundvaag J., Hole T. et al. Hepatic and renal haemodynamic changes in congestive heart disease // Tidsskr. Nor. Laegeforen. - 2006. - Vol. 126, No. 6. - P. 743-746.

18. Faure J.P., Jayle Ch., Dutheil D. et al. Evidence for protective roles of polyethylene glycol plus high sodium solution and trimetazidine against consequences of renal medulla ischemia during cold preservation and reperfusion in a pig kidney model // Nephrol. Dial. Transplant. - 2004. - Vol. 19. - P. 1742-1751.

19. Gruberg L., Mintz G.S., Mehran R. et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with preexistent chronic renal insufficiency // J. Am. Coll. Cardiol. -2000. - Vol. 36. - P. 1542-1548.

20. Gupta R., Sawhney J.P., Narain V.S. Treatment of stable angina pectoris with trimetazidine modified release in Indian primary-care practice // Am. J. Cardiovasc. Drugs. - 2005. -Vol. 5, No. 5. - P. 325-329.

21. Hauet Th., Goujon J.-M., Vandewalle A. et al. Trimetazidine reduces renal dysfunction by limiting the cold ischemia/ reperfusion injury in autotransplantation pig kidneys // J. Am. Soc. Nephrol. - 2000. - Vol. 11. - P. 138-148.

22. Katholi R.E., Taylor G.J., Woods W.T. et al. Nephrotoxicity of nonionic low-osmolality versus ionic high-osmolality contrast media: a prospective double-blind randomized comparison in human beings // Radiology. - 1993. - Vol. 186, No. 1. - P. 183187.

23. Magri P., Rao M.A.E., Cangianiello S. et al. Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin ii antagonism // Circulation. - 1998. - Vol. 98. - P. 2849-2854.

24. Marenzi G., Lauri G., Assanelli E. et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction // J. Am. Coll. Cardiol. - 2004. -Vol. 44, No. 9. - P. 1780-1785.

25. Marzilli M., Klein W.W. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials // Coron. Artery Dis. - 2003. - Vol. 14, No. 2. -P. 171-179.

26. Mehran R., Nicolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk // Kidn. Int. Suppl. - 2006. - Vol. 100. - P. S11-S15.

27. Onbasili A.O., Yeniceriglu Y., Agaoglu P. et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures // Heart. - 2007. - Vol. 93. - P. 698-702.

28. Osswald H., Muhlbauer B., Schenk F. Adenosine mediates tubuloglomerular feedback response: an element of metabolic control of kidney function // Kidney Int. - 1991. - Vol. 39 (Suppl. 32). - P. S128-131.

29. Perrone R.D., Madias N.E., Levey A.S. Serum creatinine as an index of renal function: new insights into old concepts // Clinical Chem. - 1992. - Vol. 38. - P. 1933-1953.

30. Sulikowski T., Domanski L., Ciechanowski K. et al. Effect of trimetazidine on xanthine oxidoreductase expression in rat kidney with ischemia-reperfusion injury // Arch. Med. Res. -2008. - Vol. 39, No. 4. - P. 459-462.

31. Thomsen H.S., Morcos S.K. Contrast media and kidney: European Society of Urogenital Radiology (ESUR) Guidelines // Br. J. Radiol. - 2003. - Vol. 76. - P. 513-518.